Efficacy of preoperative GLP-1 receptor agonists on the perioperative outcomes of bariatric surgery: a systematic review and meta-analysis
GLP-1 drugs before weight-loss surgery show safety but don't meaningfully improve outcomes, helping doctors make clearer decisions about prescribing in this specific setting.
This meta-analysis of 10 studies (n=5,461) found that GLP-1 receptor agonists given before bariatric surgery are safe but provide only modest preoperative weight loss with no significant improvement in postoperative outcomes or comorbidity resolution. The finding is clinically important as it clarifies the limited additive value of preoperative GLP-1 RA use in the bariatric surgery pathway, relevant given widespread GLP-1 prescribing.
What the study was
- Study design
- Systematic review and meta-analysis (10 studies, 5,461 subjects)
- Population
- Obese patients undergoing metabolic and bariatric surgery
- Sample size
- 5461
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Surgery for Obesity and Related Diseases
Why it surfaced
Large-scale meta-analysis (n=5,461) directly addresses the clinical question of preoperative GLP-1 use in bariatric candidates — a highly practical and frequently encountered scenario. The null result on postoperative outcomes has immediate clinical guideline implications.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.